Learn how Merck is using Algorithmia’s MLOps platform to accelerate vaccine research and discovery.

Merck accelerates vaccine discovery with Algorithmia

Vaccines are one of the greatest public health success stories in history. And earlier this month, I had the great pleasure of speaking with Dr. Kam Chana, Director of the Scientific Data and Computing Platforms group at Merck Research Labs, about their pioneering work using MLOps to accelerate vaccine research and discovery.

Dr. Chana and I spoke at the Ai4 2021 Healthcare Summit, where he shared how the constantly-evolving viral landscape has led vaccine research to be at the forefront of technological advancements, especially AI and machine learning.

In the session, we discussed why the pharmaceutical industry needs MLOps in order to drive innovation with AI/ML—and how Merck is using Algorithmia’s MLOps platform to accelerate their own vaccine research and discovery.

Watch the recording below to hear more from Dr. Chana.

Algorithmia: The enterprise MLOps platform

Algorithmia’s MLOps platform manages all stages of the production ML lifecycle within existing operational processes, so you can put models into production quickly, securely, and cost-effectively. See how you can get more out of your own organization’s ML efforts—watch a demo today.

The enterprise MLOps platform Put ML models into production quickly, 
securely, and cost-effectively.

Diego Oppenheimer